- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02754037
Non-alcoholic Fatty Liver Disease Parametric PET (FLiPP) Study (FLiPP)
December 13, 2023 updated by: University of California, Davis
The goal of this study is to evaluate non-invasive imaging techniques for determining liver steatosis (fat), inflammation (abnormal tissue swelling), and fibrosis (abnormal tissue scarring).In addition, the study group will be using other test measures including personal demographics, laboratory blood test results, and imaging measurements to determine the severity of NAFLD (non-alcoholic fatty liver disease), NASH (non-alcoholic steatohepatitis), inflammation, and fibrosis.
Study Overview
Status
Active, not recruiting
Detailed Description
The study group proposes to evaluate the role of fluorodeoxyglucose (FDG) positron emission tomography (PET) in the determination of steatohepatitis and in combination with MRI for detection, differentiation and quantitation of liver steatosis, steatohepatitis and fibrosis in correlation to liver biopsy.
Patient enrolled in this will already have had their liver biopsy or will be undergoing liver biopsy as a part of their clinical care as determined by their provider and will not be getting biopsies solely to be enrolled in the study.
Current treatment options for patients that liver biopsy is being performed are limited to lifestyle changes and vitamin E for patients without diabetes.
Study Type
Observational
Enrollment (Estimated)
120
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Sandeep Dhaliwal, M.D.
- Phone Number: (916) 734-8696
- Email: sandhaliwal@ucdavis.edu
Study Contact Backup
- Name: Valentina Medici, M.D.
- Phone Number: (916) 734-8696
- Email: vmedici@ucdavis.edu
Study Locations
-
-
California
-
Sacramento, California, United States, 95817
- University of California Davis Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
The study population includes those who are scheduled to have bariatric surgery (weight loss surgery) or have had a liver biopsy within the past six months with a diagnosis of Non-Alcoholic Fatty Liver Disease (NAFLD) or Non-Alcoholic Steatohepatitis (NASH).
These
Description
Inclusion Criteria:
- Patients >18 years age
- Patients who had or will have a liver biopsy as standard of care for fatty liver disease and have risk factors for NASH. Liver biopsy needs to be within 6 months of planned imaging.
- Patients undergoing bariatric surgery and will have a liver biopsy as standard of care.
- Ability to provide informed consent.
Exclusion Criteria:
- History of alcohol abuse, chronic hepatitis B or C, or other chronic liver disease other than non-alcoholic fatty liver disease.
- Pregnant women
- Prisoners
- Claustrophobic to MRI
- Allergic to FDG dye
- Patients who are unable to lie in the scanner for one hour
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PET scan parameters correlated with biopsy findings
Time Frame: one year
|
PET scan parameters correlated with biopsy findings (NAFLD Activity Score as per NASH-CRN)
|
one year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Guobao Wang, University of California, Davis
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 30, 2016
Primary Completion (Estimated)
June 30, 2024
Study Completion (Estimated)
June 30, 2024
Study Registration Dates
First Submitted
April 26, 2016
First Submitted That Met QC Criteria
April 26, 2016
First Posted (Estimated)
April 28, 2016
Study Record Updates
Last Update Posted (Estimated)
December 14, 2023
Last Update Submitted That Met QC Criteria
December 13, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 840422
- R01DK124803-01A1 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
Data will not be shared
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-alcoholic Fatty Liver Disease (NAFLD)
-
Ann & Robert H Lurie Children's Hospital of ChicagoNot yet recruitingNAFLD | Non-Alcoholic Fatty Liver Disease | Pediatric NAFLDUnited States
-
Medical College of WisconsinENDRA Life Sciences, Inc.RecruitingFatty Liver | NAFLD | Non-Alcoholic Fatty Liver Disease | Non-alcoholic Steatohepatitis | Non-alcoholic Fatty Liver | NASH | Fatty Liver DiseaseUnited States
-
Michael Ohliger, MD PhDNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingNAFLD | Non-Alcoholic Fatty Liver Disease | NASH | Non Alcoholic Fatty Liver | Non Alcoholic SteatohepatitisUnited States
-
National University Hospital, SingaporeWilmar InternationalEnrolling by invitationNAFLD | Non-Alcoholic Fatty Liver Disease | Non-Alcoholic SteatohepatitisSingapore
-
Hoffmann-La RocheCompletedFatty Liver, Non-alcoholic Fatty Liver Disease, NAFLDGermany, Austria
-
Mylan Inc.Meda Pharma S.p.A.Recruiting
-
Sohag UniversityNot yet recruitingNon-alcoholic Fatty Liver Disease NAFLD
-
Bruce A. GriffinImperial College London; University of CambridgeCompletedNon-alcoholic Fatty Liver Disease (NAFLD)United Kingdom
-
University of Southern CaliforniaWithdrawnNon-alcoholic Fatty Liver Disease (NAFLD)United States
-
Shaare Zedek Medical CenterWithdrawnNon-alcoholic Fatty Liver Disease (NAFLD)
Clinical Trials on Fluorodeoxyglucose (FDG) positron emission tomography (PET)
-
University of Wisconsin, MadisonRecruiting
-
UNC Lineberger Comprehensive Cancer CenterCompleted
-
National Cancer Institute (NCI)CompletedCervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical Cancer | Stage IVB Cervical CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterCompletedCervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma | Cervix CarcinomaUnited States
-
Samus Therapeutics, Inc.TerminatedAlzheimer DiseaseUnited States
-
UNC Lineberger Comprehensive Cancer CenterCompletedBladder CancerUnited States
-
Université de SherbrookeCanadian Cancer Society (CCS); Fonds de la Recherche en Santé du Québec; Merck... and other collaboratorsCompletedMetastatic Castration-resistant Prostate CancerCanada
-
Duke UniversityRecruitingOropharynx CancerUnited States
-
University of Wisconsin, MadisonRecruitingMelanoma | Unresectable Melanoma | Melanoma Stage IV | Melanoma Stage IIIUnited States
-
Washington University School of MedicineTerminated